In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From ViiV Healthcare

Medicaid Coverage For PrEP Without Restrictions, Cost Sharing Backed By President’s Budget

Legislation could facilitate faster access without cost sharing or restrictions for new HIV pre-exposure prophylaxis. The White House said its budget proposal to expand Medicare price negotiation would save $160bn more than the Inflation Reduction Act's existing negotiation provisions.

Medicaid Reimbursement

ViiV’s Bid To Switch HIV Patients To Cabenuva Boosted By Biktarvy Head-To-Head

A new head-to-head proves Cabenuva is a match for Gilead’s Biktarvy, which should boost uptake of the long-acting HIV treatment.

Companies Clinical Trials

Japan Q3 Roundup: Forex Impacts Majors Amid New Product Growth Expectations

Amid ongoing impact from exchange rates, Japan's five largest pharma firms showed mostly positive growth in the fiscal nine-month period. Enhertu will continue to drive Daiichi Sankyo, while Shionogi is forecasting record-breaking revenue on oral COVID-19 drug Xocova and Eisai is rolling out closely-watched Alzheimer's contender Leqembi.

Commercial Sales & Earnings

Medicare Weighing National Part B Coverage For ViiV’s HIV PrEP Apretude As ‘Preventive Service’

Unusual national coverage determination for a prevention-only drug was opened in response to a formal request from ViiV for its long-acting injectable.  

Reimbursement Medicare
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals